Document resource
Nirsevimab, a long-acting monoclonal antibody, was introduced last season (2023–2024) in some countries with the aim of reducing the burden of disease caused by respiratory syncytial virus (RSV) in infants.
Annotated abstract
Effectiveness of nirsevimab against RSV-related outcomes: findings of the 2024–2025 campaign in Catalonia align with previous analysis
archdischild · 2025-11-19 · canonical JSON source